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OBJECTIVE: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of
genotype 1 hepatitis C virus-infected patients at Brazilian reference centers.
METHODS: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients
treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013
and April 2014 at 15 reference centers in Brazil. Demographic, clinical, virological, and adverse events data were
collected during treatment and follow-up.
RESULTS: Of the 715 patients, 59% had cirrhosis and 67.1% were treatment-experienced. Based on intention-to-
treat analysis, the overall sustained viral response was 56.6%, with similar effectiveness in both groups (51.9%
for boceprevir and 58% for telaprevir, p=0.190). Serious adverse events occurred in 44.2% of patients, and
six deaths (0.8%) were recorded. Cirrhotic patients had lower sustained viral response rates than non-cirrhotic
patients (46.9% vs. 70.6%, po0.001) and a higher incidence of serious adverse events (50.7% vs. 34.8%,
po0.001). Multivariate analysis revealed that sustained viral response was associated with the absence of
cirrhosis, viral recurrence after previous treatment, pretreatment platelet count greater than 100,000/mm3, and
achievement of a rapid viral response. Female gender, age465 years, diagnosis of cirrhosis, and abnormal
hemoglobin levels/platelet counts prior to treatment were associated with serious adverse events.
CONCLUSION: Although serious adverse events rates were higher in this infected population, sustained viral
response rates were similar to those reported for other patient cohorts.
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’ INTRODUCTION
Infection with hepatitis C virus (HCV) is one of the leading
causes of chronic liver disease worldwide (1). TheWorld Health
Organization (2) currently estimates that 110 million people
have a history of HCV infection, and of these, 80 million are
chronically infected with this virus (3). Until 2011, the standard
treatment for HCV consisted of the use of PEGylated interferon
(Peg-IFN) and ribavirin (RBV), which achieved a sustained
viral response (SVR) rate of approximately 50% in patients with
HCV genotype 1 (4,5). Unfortunately, this regimen involved the
development of significant adverse events (SAEs) and a high
rate of treatment discontinuation (2). In 2011, the first direct-
acting antiviral agents were introduced into clinical practice
for the treatment of chronic hepatitis C (6-9). The protease
inhibitors boceprevir (BOC) and telaprevir (TVR) were the first
direct-acting antiviral agents used, and these drugs required
co-administration with Peg-IFN and RBV, together constituting
the so-called triple therapy. Triple therapy improved the response
rates of genotype 1 patients in clinical studies and achieved SVR
rates of 66–75% in treatment-naïve patients (6,7), 75–88% in
relapsing patients (relapsers), 52–59% in partial responders, and
29–33% in null responders (8,9).
In addition to protease inhibitors, other classes of direct-
acting antiviral agents have gradually been introduced into
clinical practice, including NS5A and NS5B inhibitors (10,11).
In this new therapeutic era, the combination of different classes
of drugs has significantly increased the rate of therapeutic
success for the treatment of chronic hepatitis C (10,11).
Moreover, these new combinations are generally safer and
do not require the use of interferon. Given its benefits, this
new therapeutic modality is currently the therapy of choice
for the treatment of chronic hepatitis C worldwide (10,11).
Between 2013 and 2015 in Brazil, triple therapy with BOC
and TVR was the standard treatment for patients infected
with HCV genotype 1 (12-13). The objective of this study
was to evaluate the effectiveness and safety of this therapeutic
modality in patients with chronic hepatitis C genotype 1
who were treated in 15 different reference centers in Brazil.
Additionally, the predictive factors for the achievement of
SVR and for the occurrence of SAEs associated with this
therapy were evaluated.
’ PATIENTS AND METHODS
Patients
This multicenter cross-sectional study included patients
chronically monoinfected with HCV genotype 1 (treatment-
naïve or previously treated with Peg-IFN and RBV) who
were treated with Peg-IFN (a2a or a2b), RBV and either BOC
or TVR according to the guidelines of the Brazilian Ministry
of Health (12,13) in 15 reference centers in Brazil. The guide-
lines of the Brazilian Ministry of Health prioritized triple
therapy for patients monoinfected with HCV genotype 1
with advanced liver disease (Metavir F3 or F4) or evidence
of portal hypertension and compensated hepatic cirrhosis
(Child-Pughp6), previously treated patients with grade 2
fibrosis (Metavir F2), or patients with extrahepatic manifes-
tation (12,13).
All patients who started treatment in these centers between
July 2013 and April 2014 were eligible for this study. The
exclusion criteria were individuals younger than 18 years
of age and individuals co-infected with human immunodefi-
ciency virus.
This study was approved by the Ethics Committee for
the Analysis of Research Projects (Comissão de Ética para
Análise de Projetos de Pesquisa–CAPPesq) of the Clinics
Hospital of the Medical School of the University of São
Paulo (Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo – HC-FMUSP) under protocol
no. 11,934.
’ METHODS
Data collection and variables analyzed
Data were collected using a standardized questionnaire.
The variables selected for analysis were grouped into the fol-
lowing different categories: 1) variables related to the patient:
age, gender, body mass index, and comorbidities; 2) vari-
ables related to HCV infection before the present treatment:
genotype 1 subtype, presence of extrahepatic manifestations,
presence of previous hepatic decompensation, the last value
recorded in medical records for hemoglobin levels, platelet
counts, albumin levels, HCV viral load, and staging of liver
fibrosis; and 3) variables related to the treatment of hepatitis
C: history of previous treatment as well as the type of viral
response observed and the occurrence of SAEs during the
current treatment. The variables analyzed in our study were
standardized according to specific considerations. For the
laboratory test conducted prior to treatment, the follow-
ing results were considered abnormal: 1- hemoglobin levels
o12 g/dL for female patients and o13 g/dL for male
patients; 2- platelet counto100,000 per mm3; and 3- albumin
levels o3.5 g/dL. Regarding hepatic fibrosis staging, liver
biopsy results obtained using the Metavir Cooperative Study
Group (14) classification and/or liver elastography were
considered. The corresponding cut-off values of transient
elastography for Metavir were 7.1 to 9.4 kPa = F2, 9.5 to
12.4 kPa = F3, and X12.5 kPa = F4 (15). Patients were also
classified as F4 if they had clinical characteristics of liver
cirrhosis defined by the presence of portal hypertension.
There was no histological or elastographic evaluation for this
group.
Regarding the type of response observed after previous
treatment with Peg-IFN and RBV, non-responders were con-
sidered those patients with any of the following types of viral
responses as a result of previous treatments: partial responders -
reduction of at least 2 log10 in HCV RNA levels at week 12 of
treatment but with detectable HCV RNA at week 24; and
null responders - reduction under 2 log10 in HCV RNA levels
at week 12 of treatment. In addition, those who did not have
a defined viral response to previous treatment were con-
sidered non-responders.
SAEs were defined as events that resulted in death, repre-
sented a threat to life, required hospitalization or prolongation
of an existing hospitalization, resulted in persistent or sig-
nificant disability, or promoted congenital malformation or
anomaly, as defined in previous studies (16). We also fol-
lowed previously established guidelines (17,18) with respect
to the presence of rash grade 3 or 4 or the presence of labora-
tory adverse events grade 3 or 4.
Treatment
The decision to initiate treatment and the choice between
BOC or TVR and Peg-IFN-a2a (180 mg) or Peg-IFN-a2b
(1.5 mg/kg) was entirely at the discretion of the attending
physician of each participating service, according to the
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guidelines of the Brazilian Ministry of Health and the prod-
uct manufacturers (19,20).
Monitoring of HCV RNA
HCV RNA levels were measured at weeks 4 and 12 of
treatment, at the end of therapy and at weeks 12 and/or
24 after the end of therapy. We performed real-time poly-
merase chain reaction (PCR) with a detection limit of 12 IU/mL
(Abbott Molecular, Des Plaines, IL) (21) for these measurements.
The rapid viral response (RVR) was defined as undetect-
able HCV RNA (o12 IU/mL) at week 8 for those treated
with BOC and week 4 for those treated with TVR (we con-
sidered week 8 to be when ‘‘lead in’’ was performed).
Evaluation of effectiveness
Effectiveness was evaluated using the intention-to-treat
principle. The primary outcome of the study was SVR, which
was defined as undetectable levels of HCV RNA (o12 IU/mL)
at least 12 weeks after discontinuation of treatment.
Assessment of safety
The safety of triple therapy using BOC and TVR was asses-
sed by determining the occurrence of SAEs during treatment.
Statistical analysis
A descriptive analysis of the baseline demographic and
clinical characteristics was performed. The results are presented
as frequency tables for qualitative variables; central tendency
and dispersion measures were estimated for quantitative vari-
ables. Pearson’s chi-square test was used to compare the patients
according to the treatment provided. Fisher’s exact test was
used for situations in which this test was not appropriate.
Student’s t-test or the Mann-Whitney U-test was applied for
continuous variables as required.
The prevalence of treatment effectiveness, rate of SAE occur-
rence, and respective 95% confidence intervals (95% CIs) were
calculated. The factors associated with the effectiveness of
treatment and SAE occurrence were determined in patients
with chronic hepatitis C by performing a bivariate analysis and
determining the prevalence ratios (PRs) and respective 95% CIs.
Variables with p-values smaller than 0.20 as determined by
performing bivariate analysis were selected for multivariate
analysis. The Poisson regression model with robust variance
was used in the bivariate and multivariable analyses. PRs
and their 95% CIs were estimated for each of the variables in
each final model. A significance level of 5% was adopted.
’ RESULTS
Patient characteristics
A total of 715 adult patients with chronic HCV infection
were included in this study. The majority of patients were
male (56.1%), with a mean age of 54.1±10.1 years; 267
individuals (37.3%) had HCV subtype 1a, and 315 (44.1%)
had subtype 1b. Among the studied patients, 422 (59%) had
liver cirrhosis, and 67.1% were treatment-experienced. In
total, 557 patients (77.9%) received treatment with Peg-IFN,
RBV, and TVR, and 158 (22.1%) patients received treatment
with Peg-IFN, RBV, and BOC.
Table 1 shows the baseline characteristics of the patients
according to treatment group (BOC vs. TVR). Patients treated
with BOC reported a higher prevalence of extrahepatic
manifestations before treatment and a more frequent history
of previous hepatic decompensation than those treated with
TVR (13.3 vs. 3.9%, po0.001 and 6.3 vs. 2.2%, p=0.007,
respectively). However, there was a predominance of
treatment-naïve patients in the group treated with TVR
compared to the number in the group treated with BOC
(35.2 vs. 24.7%, p=0.045). Regarding the laboratory tests
conducted before treatment, abnormal hemoglobin levels
[o12 g/dL (women), o13 g/dL (men)] and platelet counts
o100,000/mm3 in the BOC group were significantly more
frequent in the BOC group than in the TVR group (10.9 vs.
4.6%, p=0.004 and 24.4 vs. 17.1%, p=0.040).
Effectiveness
According to the intention-to-treat analysis (n=715), the
overall percentage of patients with SVR was 56.6% (95% CI,
52.9–60.3%). The effectiveness of treatment between the
Table 1 - Baseline characteristics of patients with hepatitis C
according to the antiviral treatment received.
VARIABLES BOCEPREVIR
(n = 158)
TELAPREVIR
(n = 557)
p
N % N %
Gender 0.246
Male 95 60.1 306 54.9
Female 63 39.9 251 45.1
Age (years)* 0.735
p65 138 87.9 495 88.9
465 19 12.1 62 11.1
BMI (kg/m2)** 0.341
Mean (SD) 27.4 (4.5) 27.3 (4.7)
Median (min - max) 26.7
(20.6–41.6)
26.6
(18.0–43.4)
Number of comorbidities 0.192
o2 108 68.4 410 73.6
X2 50 31.6 147 26.4
Extrahepatic manifestations o0.001
No 137 86.7 535 96.1
Yes 21 13.3 22 3.9
Previous hepatic decompensation 0.007
No 148 93.7 545 97.8
Yes 10 6.3 12 2.2
Genotype 1 subtype 0.314
1a 51 32.3 216 38.8
1b 74 46.8 241 43.3
1a/1b or 1 33 20.9 100 18.0
Stage of liver fibrosis 0.096
F1+F2 18 11.4 35 6.3
F3 51 32.3 189 33.9
F4 89 56.3 333 59.8
Treatment history 0.045
Relapser 45 28.5 141 25.3
Non-responder 74 46.8 220 39.5
Treatment-naı¨ve 39 24.7 196 35.2
Hemoglobin levels before treatment (g/dL)*** 0.004
Normal 139 89.1 514 95.4
Abnormala 17 10.9 25 4.6
Platelet count before treatment (per mm3)*** 0.040
X100,000 118 75.6 447 82.9
o100,000 38 24.4 92 17.1
Albumin levels before treatment (g/dL)# 0.760
X3.5 147 96.1 510 95.5
o3.5 6 3.9 24 4.5
HCV RNA levels before treatment (IU/mL)## 0.756
o800,000 71 45.8 253 46.4
X800,000 84 54.2 292 53.6
Missing data: (*) 1; (**) 110; (***) 20; (#) 28; (##) 15
ao12 g/dL (women), o13 g/dL (men)
BMI, body mass index; HCV, hepatitis C virus.
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groups that received BOC or TVR was similar (51.9 vs. 58.0%;
p=0.190). However, the SVR rate was higher in patients
without cirrhosis than in patients with cirrhosis (70.6 vs.
46.9%, po0.001). Taking into account a history of previous
treatment, SVR rates were 59.1% for treatment-naïve patients,
74.3% for relapsers, and 43.2% for non-responders (60% for
prior partial responders and 33.5% for null responders)
(po0.001) (Figure 1). Of the 310 patients who did not achieve
SVR, 148 (47.7%) patients had viral failure during treatment,
87 (28.1%) patients discontinued treatment because of adverse
events, 69 (22.3%) patients relapsed, and 11 (3.5%) patients
abandoned treatment.
The results obtained for the 2 groups of patients were then
combined to identify factors associated with treatment
effectiveness. The results of the univariate and multivariate
analyses are shown in Table 2. The variables defined as
predictors of achievement of SVR were the presence of liver
cirrhosis (PR, 0.77; 95% CI, 0.68–0.87; po0.001), history of
previous treatment in non-responders (PR, 0.69; 95% CI,
0.59–0.81; po0.001), being treatment-naïve (PR, 0.83; 95% CI,
0.73–0.95; po0.001) vs. being a relapser, a platelet count
o100,000/mm3 prior to treatment (PR, 0.6; 95% CI, 0.46–
0.77; po0.001), and the presence of RVR (PR 1.9; 95% CI,
1.58–2.30; po0.001).
Safety
Of the 715 patients, 316 (44.2%; 95% CI, 40.5–47.9) had
at least one SAE episode. A total of 581 SAE episodes
were observed. The SAE rate was significantly higher among
patients with cirrhosis than among patients without cirrhosis
(50.7 vs. 34.8%, po0.001). Premature discontinuation of treat-
ment in cases of SAE was observed in 121 (16.9%) patients,
and the most common SAEs were hepatic decompensation
(n=28), anemia (n=23), and infection (n=20). Furthermore, six
deaths (0.8%) were observed among the treated patients.
Most of these cases were associated with infections, includ-
ing spontaneous bacterial peritonitis (n=1), septic arthritis
(n=1), and skin sepsis (n=1). Other causes of death included
hepatorenal syndrome (n=1), pulmonary embolism (n=1),
and cerebral aneurysm (n=1).
Table 3 compares patient safety profiles according to
treatment group (BOC vs. TVR). Patients treated with TVR
had a higher frequency of degree 3 or 4 anemia than patients
treated with BOC and an increased need for blood transfu-
sion (26.9 vs. 19.0%, p=0.042 and 13.5 vs. 6.3%, p=0.014,
respectively).
According to a multivariate analysis, the factors associated
with the occurrence of SAEs were female gender (PR, 1.42;
95% CI, 1.21–1.67; po0.001), age465 years (PR, 1.32; 95% CI
1.07–1.62; p=0.008), the presence of liver cirrhosis (PR, 1.25;
95% CI, 1.04–1.52; p=0.019), and abnormal hemoglobin levels
or platelet counts before treatment (PR, 1.56; 95% CI, 1.23–
1.98; po0.001 and PR, 1.54; 95% CI, 1.30–1.82; po0.001,
respectively) (Table 4).
’ DISCUSSION
Based on our results, 56.6% of patients with chronic
hepatitis C treated with therapies involving the use of BOC
or TVR achieved SVR. Multivariate analysis indicated that
Figure 1 - Rates of SVR in patients with chronic hepatitis C genotype 1 treated with first-generation protease inhibitors. (A) Overall SVR
according to the protease inhibitor used. (B) SVR according to the presence of cirrhosis. (C) SVR according to the history of previous
treatment.
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the factors associated with the achievement of SVR were the
absence of cirrhosis, a history of relapse after previous
treatment with Peg-IFN and RBV, a platelet count4100,000/mm3
before therapy, and the presence of RVR. Regarding treatment
safety, approximately 44.2% of study patients had SAEs.
Multivariate analysis indicated that the factors associated with
the occurrence of SAEs were the presence of liver cirrhosis,
female gender, age 465 years, and abnormal hemoglobin
levels or platelet counts before treatment.
Comparison of our results with those observed in other
large real-life cohorts involving the use of triple therapy
with BOC or TVR suggested the rate of SVR was similar to
that observed in previous studies, in which this rate ranged
between 44% and 58% (22-24) (Table 5). However, notably, in
our sample there was a higher frequency of patients with
cirrhosis (59%) than in the samples of other real-life studies,
in which this rate ranged between 16% and 44% (22-24). To a
certain extent, these results suggested a slightly higher SVR
rate in our study considering our sample had a higher
frequency of patients with advanced disease. In addition, our
results constitute a profile of patients primarily treated in
Brazil, i.e., patients with advanced liver disease, which is in
accordance with the guidelines recommended by the
Ministry of Health of Brazil.
The presence of liver cirrhosis has often been associated
with a lower likelihood of SVR in the treatment of chronic
hepatitis C, regardless of the treatment used (23-26). The
mechanisms that determine a lower likelihood of cure are
poorly understood. However, these factors likely include
impaired immune response in patients with cirrhosis and
lower responsiveness to the proposed treatment, limited
distribution of drugs in the compromised liver parenchyma,
and factors associated with drug toxicity in this group of
patients (27). Our results corroborate this hypothesis, as we
observed an SVR rate of 46.9% in patients with cirrhosis and
70.6% in patients without cirrhosis.
With respect to the SVR rates observed in our study for
non-responders to previous treatments with Peg-IFN and
RBV, our results corroborate those obtained in registration
studies with BOC (6,8) and TVR (7,9) and in studies with
Table 2 - Results of univariate and multivariate analyses of factors associated with sustained viral response in patients with hepatitis C
infection.
Univariate analysis Multivariate analysis
PR 95% CI p PR 95% CI p
Boceprevir (versus Telaprevir) 0.89 0.76–1.06 0.190
Genotype 1 subtype 0.010
1a 1
1b 1.23 1.07–1.43
1a/1b or 1 1.05 0.86–1.28
Cirrhosis 0.66 0.59–0.75 o0.001 0.77 0.68–0.87 o0.001
Treatment history o0.001 o0.001
Relapser 1 1
Non-responder 0.58 0.49–0.68 0.69 0.59–0.81
Treatment-naı¨ve 0.79 0.69–0.91 0.83 0.73–0.95
Abnormal hemoglobin levels before treatment*a 1.19 0.95–1.49 0.124
Platelet count o100,000 per mm3 before treatment* 0.49 0.38–0.64 o0.001 0.6 0.46–0.77 o0.001
Albumin levels o3.5 g/dL before treatment** 0.76 0.50–1.15 0.193
HCV RNA X800,000 IU/mL before treatment# 0.90 0.79–1.02 0.101
RVR 1.98 1.64–2.40 o0.001 1.9 1.58–2.30 o0.001
Occurrence of SAEs 0.82 0.72–0.94 0.005
Hepatic decompensation 0.56 0.36–0.88 0.012
Infection 0.83 0.64–1.08 0.158
Missing data: (*) 20; (**) 28; (#) 15
ao12 g/dL (women), o13 g/dL (men)
RVR, rapid viral response
PR, prevalence ratio
95% CI, 95% confidence interval.
Table 3 - Distribution of patients with chronic hepatitis C
according to the occurrence of SAEs and the treatment received.
VARIABLES BOCEPREVIR
(n=158)
TELAPREVIR
(n=557)
p
N % N %
Grade 3 or 4 anemia 0.042
No 128 81.0 407 73.1
Yes 30 19.0 150 26.9
Blood transfusion 0.014
No 148 93.7 482 86.5
Yes 10 6.3 75 13.5
Grade 3 or 4 rash 0.439a
No 155 98.1 538 96.6
Yes 3 1.9 19 3.4
Grade 4 neutropenia 0.222
No 144 91.1 523 93.9
Yes 14 8.9 34 6.1
Grade 3 or 4 thrombocytopenia 0.063
No 147 93.0 489 87.8
Yes 11 7.0 68 12.2
Hepatic decompensation 0.103
No 145 91.8 530 95.2
Yes 13 8.2 27 4.8
AE that led to discontinuation
of treatment
0.587
No 129 81.6 465 83.5
Yes 29 18.4 92 16.5
Death 0.999a
No 157 99.4 552 99.1
Yes 1 0.6 5 0.9
AE, adverse event
a Fisher’s exact test.
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real-life cohorts (23,28-30). Overall, relapsers have a higher
likelihood of achieving SVR after triple therapy with BOC
or TVR. In phase 3 studies with these drugs, relapsers were
the most eligible candidates for triple therapy with BOC and
TVR and achieved SVR rates between 75% (8) and 88% (9),
respectively. Our study corroborates this finding, given the
SVR rate of 74.7% observed among relapsers to previous
treatments with Peg-IFN and RBV. Among non-responders,
this rate was 43.2% in our sample, which is similar to that
reported in clinical studies using BOC and TVR (29-59%,
including partial responders and null responders) (8,9).
RVR was the best predictor of treatment success (SVR)
in our cohort (OR 1.9, 95% CI, 1.58–2.30) and in other clinical
studies (30,31). However, in our study, the impact of extended
RVR was not assessed because this information was not
available for analysis in 21% of patients.
Regarding treatment safety, we observed a high preva-
lence of SAEs in our study group (44.2%); this rate was
higher than that reported in phase 3 studies for BOC (8) and
TVR (7,9) and in other real-life studies (22,28,32,33) (Table 5).
However, this result was similar to that obtained in the
CUPIC study (49.9%) (29), likely due to the large number of
patients with advanced liver disease in our study, which was
conducted at tertiary referral centers where patients usually
have diseases that are more complex. Based on our results,
SAEs occurred in 50.7% of patients with cirrhosis and 34.8%
of patients without cirrhosis. The higher prevalence of
SAEs in cirrhotic patients is also in accordance with other
previously published studies (29,32).
The most important factors associated with the occurrence
of SAEs were the presence of liver cirrhosis, female gender,
age 465 years, and abnormal hemoglobin levels or platelet
counts before treatment. All of these factors have been
extensively described in studies similar to ours (29,32). These
findings underscore the strong association between the occur-
rence of SAEs during the treatment of hepatitis C and the
presence of advanced liver disease (29,32).
Despite the high prevalence of SAEs in our study, the rate
of discontinuation of therapy due to adverse events was low
(16.9%) compared to rates observed in real-life studies
(29,33,34) and was similar to that reported for the REALIZE
registration study (9). These rates vary widely in the
literature, ranging between 6.8% and 21.1% (22,28,29,33,34).
This wide variability may reflect the clinical heterogeneity of
the groups of patients included in the different studies. The
low rate of treatment discontinuation observed in our study
may be justified by the timeframe for the introduction of
these drugs in Brazil compared to other countries. Therefore,
information on the management of these patients, specifi-
cally concerning adverse events and the adjustment of
ribavirin administration compared to other foreign services,
may facilitate the safer handling of these drugs. However,
the mortality rate observed in our cohort was similar to that
observed in other real-life studies (22,28,29,32,33).
We believe that this study describes the largest cohort
of patients infected with HCV genotype 1 and treated with
BOC or TVR in combination with Peg-IFN and RBV in a real-
life context in Latin America. We sought to include patients
from different Brazilian service centers and with different
characteristics to obtain a representative sample of patients
during this phase of treatment for hepatitis C in Brazil.
However, this study has some limitations. The first limitation
is its cross-sectional, retrospective, observational, and multi-
centric nature. In this type of study, the leading center
researchers involved are fully responsible for the choice of
treatment offered and for providing the data. In this respect,
the selection of patients for treatment and the choice between
different treatments is at the discretion of the local investigator.
Table 4 - Univariate and multivariate analysis of the occurrence of SAEs in patients with hepatitis C infection.
Univariate analysis Multivariate analysis
PR 95% CI p PR 95% CI p
Female gender 1.47 1.25–1.73 o0.001 1.42 1.21–1.67 o0.001
Age 465 years* 1.50 1.24–1.82 o0.001 1.32 1.07–1.62 0.008
X2 comorbidities 1.29 1.09–1.53 0.003
Previous hepatic decompensation 1.46 1.05–2.03 0.023
Cirrhosis 1.46 1.21–1.75 o0.001 1.25 1.04–1.52 0.019
Abnormal hemoglobin levels before treatment*a 1.48 1.16–1.89 0.001 1.56 1.23–1.98 o0.001
Platelet count o100,000 per mm3 before treatment* 1.72 1.47–2.02 o0.001 1.54 1.30–1.82 o0.001
Albumin levels o3.5 g/dL before treatment** 1.44 1.09–1.92 0.012
Missing data: (*) 20; (**) 28
ao12 g/dL (women), o13 g/dL (men)
PR, prevalence ratio
95% CI, 95% confidence interval.
Table 5 - Effectiveness and safety of real-life studies with boceprevir and telaprevir.
Author (Ref.) PI Country n Cirrhosis SVR (%) SAE (%) Deaths (n)
Mauss (22) BOC, TVR Germany 1087 16% 58% 9% 3%
Backus (23) BOC, TVR USA 835 27% (BOC) 44% (TVR) 50% (BOC) 52% (TVR) NA NA
Sterling(24)/Gordon (33) BOC, TVR USA 2084 38% 44% (BOC) 54% (TVR) 12% 5
Calleja (28) BOC Spain 170 79% 47% 37% 2
Hezode (29) BOC, TVR France 511 100% 40% 50% 11
Callefi BOC, TVR Brazil 715 59% 56% 44% 6
Ref.: reference. PI: protease inhibitor. BOC: boceprevir. TVR: telaprevir. n: number. SRV: sustained viral response. SAE: serious adverse event. NA: not
available.
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This type of study may lead to selection bias for the patients
included. Moreover, in this study, it was not possible to
determine how many patients with chronic HCV infection
and treatment indication were initially considered eligible for
treatment or refused treatment. We cannot exclude the
possibility that patients selected for treatment who had a
higher likelihood of achieving SVR were included in our
analysis. However, we believe that by following the stan-
dards described in the Brazilian protocol at the time (12,13)
and including all patients treated consecutively in each center
during the study period, we may have reduced the likelihood
of selection bias.
Another potential bias in our study is the possibility
of missing data, as only the data recorded in the medical
records of the patients were included in the study. This has
also been the case in other retrospective studies. In terms of
monitoring of adherence to treatment, it was not possible to
access this information due to the retrospective nature of this
study. However, it is important to note that in our study, only
variables that did not exceed 15% patient loss were included
for analytical purposes. Conversely, to evaluate the effec-
tiveness of treatment in clinical practice, real-life studies offer
the advantage of eliminating the potential bias of a change in
behavior and conduct that might occur during the execution
of a prospective study (35). Therefore, the retrospective nature
of our study may be advantageous because it provides a true
assessment of the effectiveness of this type of therapy in Brazil.
According to data from the Brazilian Ministry of Health,
approximately 7,800 treatments with BOC or TVR were
performed at the national level between 2012 and 2016 (36).
We believe our sample represents a significant and repre-
sentative percentage of this group of patients and provides
valuable information about this experience with real-life data
from treated patients.
In conclusion, although most of our patients achieved
SVR after treatment, the rate of SAEs was very high in this
population. Patients with cirrhosis had a lower risk of
achieving SVR and an increased risk of developing SAEs.
Therefore, despite the beneficial outcome and cure of a
significant number of patients, the risk of the development of
SAEs, including severe clinical complications and death,
particularly in those with advanced liver disease, should be
taken into consideration. In addition, the use of therapies such
as BOC or TVR has been proscribed, and safer, more effective
direct-acting drugs should be considered. Our results confirm
the need to reformulate the guidelines for the treatment of
chronic hepatitis C in Brazil, which recently incorporated safer
and more effective drugs for the treatment of this condition.
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